Lupin gets USFDA nod for Bromfenac
Pharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery.
Lupin buys 2 diabetes brands from Boehringer Ingelheim
New Delhi: Pharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bromfenac Ophthalmic Solution 0.09 per cent, Lupin said in a regulatory filing. The product is the generic equivalent of Bromday Ophthalmic Solution 0.09 per cent of Bausch + Lomb, it added. The product will be manufactured at Lupin’s Pithampur facility in Madhya Pradesh, the company said. Bromfenac Ophthalmic Solution 0.09 per cent had estimated annual sales worth $ 11 mn in the US.
